TrialCurveACE-Breast-02: reconstructed Kaplan–Meier curves
ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Signal Transduct Target Ther. 2025 Feb 17;10:56. doi: 10.1038/s41392-025-02149-3 |
|---|---|
| DOI | 10.1038/s41392-025-02149-3 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival assessed by BICR
From figure panel a · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: ARX788 11.0 months; LC 8.1 months. Survival at 12 months: ARX788 49%; LC 31%. Hazard ratio ARX788 vs LC 0.65 (95% CI 0.51–0.84).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| ARX788 | 221 | 109 | 11.0 |
| LC | 220 | 134 | 8.1 |
- ARX788 vs LC: reconstructed HR 0.65 (95% CI 0.51–0.84)
Landmark survival (reconstructed)
| Time | ARX788 | LC |
|---|---|---|
| 6 mo | 67.2% | 59.7% |
| 12 mo | 48.8% | 30.7% |
| 18 mo | 29.3% | 9.6% |
| 24 mo | 22.3% | 9.6% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.64, reconstructed 0.652 pass
Progression-free survival assessed by INV
From figure panel b · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: ARX788 10.0 months; LC 7.2 months. Survival at 12 months: ARX788 45%; LC 30%. Hazard ratio ARX788 vs LC 0.64 (95% CI 0.50–0.82).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| ARX788 | 221 | 113 | 10.0 |
| LC | 220 | 156 | 7.2 |
- ARX788 vs LC: reconstructed HR 0.64 (95% CI 0.50–0.82)
Landmark survival (reconstructed)
| Time | ARX788 | LC |
|---|---|---|
| 6 mo | 66.8% | 60.1% |
| 12 mo | 45.0% | 29.6% |
| 18 mo | 28.2% | 8.2% |
| 24 mo | 21.4% | 5.4% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.64, reconstructed 0.643 pass
Overall survival
From figure panel · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: ARX788 not reached; LC not reached. Survival at 12 months: ARX788 87%; LC 82%. Hazard ratio ARX788 vs LC 0.72 (95% CI 0.47–1.11).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| ARX788 | 221 | 35 | not reached |
| LC | 220 | 49 | not reached |
- ARX788 vs LC: reconstructed HR 0.72 (95% CI 0.47–1.11)
Landmark survival (reconstructed)
| Time | ARX788 | LC |
|---|---|---|
| 6 mo | 94.4% | 93.9% |
| 12 mo | 86.8% | 82.0% |
| 18 mo | 81.1% | 70.0% |
| 24 mo | 75.1% | 58.1% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.71, reconstructed 0.721 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- PEONY: Disease-free survival (DFS); Event-free survival (EFS)
- PATHWAY: Overall survival; Progression-free survival by blinded independent central review; Progres
- PANTHER: Breast cancer recurrence-free survival events (cumulative incidence)
- Culmerciclib + fulvestrant in HR+/HER2− breast cancer: Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials